chrisvoncsefalvay/vaers-outcomes huggingface dataset:
I have been fatigued and achy all over since 6:00 PM on the day I received the shot. It has been eight days. My lymph nodes at my collarbone and under my arm on my left side or swollen. That began the day after, Sunday, October 3. They are currently smaller but still swollen. I still ache all over and I feel terrible. I have tried to stay moderately active. I normally work out six days a week. I have done just three very light workouts this past week, thinking that might help. But it hasn?t. I have drank lots of water and tried to eat right. I am afraid of getting the second shot because I still feel so bad from the first. This is almost as bad as having Covid back in January.
Intermittent nausea (no vomiting), no fever for four days (continuing)
Five day post vaccination, the patient began to experience swelling of all of her joints. She also loss strength. She states that the pain was "excruciating".
pt recvd vax 28AUG92 & 25SEP92 sx persisted along w/swelling of the joints around the fingers; seen by MD; dx degenerative joint disease in the first MP joints in the feet bilaterally was made;
Flu-like symptoms; It affected my knee ,It started hurting last night/ worsening knee pain; I had chills; This spontaneous case was reported by a patient and describes the occurrence of INFLUENZA LIKE ILLNESS (Flu-like symptoms), ARTHRALGIA (It affected my knee ,It started hurting last night/ worsening knee pain) and CHILLS (I had chills) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     Allergies related to medications, food and other products were unknown.  It was unknown if patient ever have tested or diagnosed positive for COVID.  History related to o mentioned adverse event and both acute and chronic illnesses at the time of vaccination was unknown.  Information about other vaccines given within 1 month prior to Moderna COVID-19 vaccine was unknown.    On 25-Apr-2022 at 2:00 PM, the patient received fourth dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 25-Apr-2022, the patient experienced INFLUENZA LIKE ILLNESS (Flu-like symptoms), ARTHRALGIA (It affected my knee ,It started hurting last night/ worsening knee pain) and CHILLS (I had chills). The patient was treated with PARACETAMOL (TYLENOL [PARACETAMOL]) on 26-Apr-2022 at an unspecified dose and frequency. In April 2022, INFLUENZA LIKE ILLNESS (Flu-like symptoms) and CHILLS (I had chills) had resolved. At the time of the report, ARTHRALGIA (It affected my knee ,It started hurting last night/ worsening knee pain) had not resolved.     No concomitant medication information was provided.  Patient mentioned that she was going to physical therapy and stated that they put patient on a new machine and it affected her knee. The patient stated that she had ice on her knee and also asked whether she can take Advil.  Patient had not seeked medical care.   Reporter did not allow further contact   Most recent FOLLOW-UP information incorporated above includes: On 26-Apr-2022: Follow-up document received and includes no new information.
patient developed nausea/vomiting, fatigue, muscle aches, nasal congestion, and headache starting on 07/24.  She tested positive for COVID on 07/25.
This spontaneous case was reported by a respiratory therapist and describes the occurrence of PRODUCT ADMINISTRATION ERROR (doses given after temperature excursion) and PRODUCT TEMPERATURE EXCURSION ISSUE (20 minute excursion in the freezer that their Moderna COVID-19 vials were stored in) in a 40-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 039F21A) for COVID-19 vaccination. No Medical History information was reported. On an unknown date, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced PRODUCT ADMINISTRATION ERROR (doses given after temperature excursion) and PRODUCT TEMPERATURE EXCURSION ISSUE (20 minute excursion in the freezer that their Moderna COVID-19 vials were stored in). At the time of the report, PRODUCT ADMINISTRATION ERROR (doses given after temperature excursion) and PRODUCT TEMPERATURE EXCURSION ISSUE (20 minute excursion in the freezer that their Moderna COVID-19 vials were stored in) had resolved. For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments. No concomitant product was provided by the reporter. No treatment medication was provided.
REGULAR COLD FOR 7 DAYS; This spontaneous report received from a patient concerned a male of unspecified age. The patient's weight, height, and medical history were not reported. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin, and batch number were not reported) dose, start therapy date were not reported for covid-19 prophylaxis. The batch number was not reported and has been requested. No concomitant medications were reported. On an unspecified date, the patient experienced regular cold for 7 days. Laboratory data (dates unspecified) included: COVID-19 virus test false-positive (Binax test). The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient recovered from regular cold for 7 days. This report was non-serious.
Pt died 26OCT91 attributed to SIDS per autopsy 28OCT91;
Fever; chills; headache; body aches; This is a spontaneous report from a contactable consumer or other non healthcare professional. A 32 year old male patient received bnt162b2 (BNT162B2), dose 2 via an unspecified route of administration, administered in Arm Right on 01Mar2021 (Batch/Lot number was not reported) as DOSE 2, SINGLE for covid-19 immunisation. Medical history and concomitant medications were not reported. The patient previously took bnt162b2 for covid-19 immunisation, aspirin and experienced drug hypersensitivity. The patient experienced fever, chills, headache and body aches on 01Mar2021 with outcome of recovering.  No follow up attempts are possible. Information about lot/batch number cannot be obtained.
This is a spontaneous report from a contactable consumer (patient). A 25-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0183) via an unspecified route of administration in the left arm on 05May2021 at 16:30 (at the age of 25-years-old) as a single dose for COVID-19 immunisation. Medical history included several pneumonia cases back-to-back in childhood that required hospitalization and mainly affected the patient's left lung. The patient did not have any known allergies. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications were not reported. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8731) via an unspecified route of administration in the left arm on 14Apr2021 at 16:45 (at the age of 25-years old) as a single dose for COVID-19 immunisation and experienced soreness. The patient reported that it had been a little over 24 hours since her second dose. On 05May2021, on the day of the vaccination, the patient did not experience anything. The patient was actually really surprised at how little soreness she felt, in comparison to the first dose. However, today on 06May2021 at 09:45, the patient experienced what she could best describe as the typical signs that a heavy cold was fixing to knock one out in the coming days. The patient had ongoing moderate body aches, internal fever, a slight headache, and, what seemed unusual to her, slight chest pain. The patient felt it specifically on her left side, almost as if over the heart. There was also a slight intermittent ache in her left armpit. But specifically to the chest pain, the patient mainly felt it upon exhaling deeply. No other symptoms thus far to report at the time of this report. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. No therapeutic measures were taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events the typical signs that a heavy cold is fixing to knock "you" out in the coming days, little soreness/moderate body aches, internal fever, slight headache, slight chest pain and slight intermittent ache in left armpit was not recovered at the time of this report. No follow-up attempts are needed. No further information is expected.
Patient received the H1N1 vaccine at 3:25 PM and broke out in hives.
Rash started from day 7 to day 12 and is getting bigger; A spontaneous report (United States) was received from a consumer (age and gender unknown) who received Moderna's COVID-19 vaccine and experienced rash which started from day 7 to day 12 and is getting bigger.  The patient's medical history was not provided. No relevant concomitant medications were reported.   On an unspecified date, prior to the onset of the events, the patient received their first of two planned doses of mRNA-1273 (batch unknown) intramuscularly for prophylaxis of COVID-19 infection.   On an unspecified date, patient started to experience rash from day 7 to 12 and it got bigger. No treatment information was provided.  Action taken with the second dose of mRNA-1273 in response to the event was not reported.   The outcome for the events of rash which started from day 7 to day 12 and is getting bigger was not recovered.; Reporter's Comments: This case concerns a 72-year-old female who experienced the nonserious unexpected event of RASH.  Event onset 7-12 days after the first dose of mRNA-1273. Treatment not reported. Event ongoing. Based on current available information and temporal association between the use of the product and the start date of the event, a causal relationship cannot be excluded.
Itchy papular red rash on face under chin anterior neck and upper chest extending into ears; persists yet a week later despite MEDROL dose pack and Tamarac.
"Delayed hypersensitivity reaction"; Very faint pink freckles on top of both feet and on both armpits; Rash on her right hip; Rash at injection site and distal to it; Perimeter was raised; This spontaneous case was reported by a consumer and describes the occurrence of TYPE IV HYPERSENSITIVITY REACTION ("Delayed hypersensitivity reaction"), EPHELIDES (Very faint pink freckles on top of both feet and on both armpits), RASH (Rash on her right hip), VACCINATION SITE RASH (Rash at injection site and distal to it) and VACCINATION SITE SWELLING (Perimeter was raised) in a 76-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 030M20A and 026A21A) for COVID-19 vaccination.     Concurrent medical conditions included Dust allergy (dust mites), Allergy to feathers, Ragweed allergy, Pollen allergy (trees), Hypersensitivity and Antifungal treatment. Concomitant products included LEVOTHYROXINE SODIUM (THYROXINE), OXYMETAZOLINE HYDROCHLORIDE (CLARITIN ALLERGIC) and DOXYCYCLINE for an unknown indication.   On 03-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 03-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 03-Feb-2021, the patient experienced VACCINATION SITE RASH (Rash at injection site and distal to it) and VACCINATION SITE SWELLING (Perimeter was raised). On 08-Feb-2021, the patient experienced TYPE IV HYPERSENSITIVITY REACTION ("Delayed hypersensitivity reaction") and EPHELIDES (Very faint pink freckles on top of both feet and on both armpits). 08-Feb-2021, the patient experienced RASH (Rash on her right hip). The patient was treated with CORTISONE at an unspecified dose and frequency. At the time of the report, TYPE IV HYPERSENSITIVITY REACTION ("Delayed hypersensitivity reaction"), EPHELIDES (Very faint pink freckles on top of both feet and on both armpits), RASH (Rash on her right hip), VACCINATION SITE RASH (Rash at injection site and distal to it) and VACCINATION SITE SWELLING (Perimeter was raised) outcome was unknown.        mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) dosing remained unchanged.       Treatment for the event includes herbal cream called "arnica".   Most recent FOLLOW-UP information incorporated above includes: On 18-May-2021: significant follow-up appended into AER MOD-2021-051168, Email ID was updated , AE contact information updated, events was updated.
Approximately 8 hours later, sudden onset of extreme chills accompanied by aches and fatigue; subsided after taking Tylenol. Next day, approximately 24 hours of fatigue, minor aches, headache, and fever.
8 cm area of erythema does not appear to be cellulitis advised may be allergic to Td.
Case number PHEH2015US005323, is an initial spontaneous report from a pharmacist received on 17 Mar 2015. This report refers to a patient of unknown age and gender. Past medical history and concomitant medication were not reported. On an unknown date, the patient was vaccinated with FLUVIRIN (batch number: unknown) via intradermal. No adverse event was reporting following this administration error.
23JAN92 h/a, dizziness, irritable; 24JAN92 sore neck, lump below lt ear, irritable;
flublok given to 16 year old, only recommended for 18 and older, no adverse events
Itching all over body at different times, mostly the head, it comes and goes but worse towards night time hours.... tiny pimples come and go also.
This spontaneous report was received from a physician concerning a 65 year old male patient with allergy/drug reaction to non-steroidal anti-inflammatory drug. On 31-JUL-2014, the patient was vaccinated with a dose of PNEUMOVAX23 lot# J007786, expiration date 25-SEP-2014 (also reported as 08-MAR-2015), 0.5 ml, intramuscular. Co-suspect and concomitant therapies were not reported. Physician reported that on 02-AUG-2014, patient experienced induration, erythema at the injection site and temperature of 101.7, after receiving PNEUMOVAX23. At the time of the report, induration and erythema at the injection site has persisted; however, temperature has resolved, in August 2014. Patient received treatment with an ice pack and Tylenol and seek medical attention. Additional information has been requested.
fever and stomach cramping, this is patients first pregnancy, delivery date is August 21, 2021
Hard to lift left arm; Injection site pain; This spontaneous case was reported by a consumer and describes the occurrence of PAIN IN EXTREMITY (Hard to lift left arm) and INJECTION SITE PAIN (Injection site pain) in an 87-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 045AZIA) for COVID-19 vaccination.     No Medical History information was reported.    On 21-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 21-Mar-2021, the patient experienced PAIN IN EXTREMITY (Hard to lift left arm) and INJECTION SITE PAIN (Injection site pain). At the time of the report, PAIN IN EXTREMITY (Hard to lift left arm) and INJECTION SITE PAIN (Injection site pain) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.
No adverse event; An expired dose of Moderna Covid-19 vaccine was administered to a 10 yr old patient.; This spontaneous case was reported by a pharmacist and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (An expired dose of Moderna Covid-19 vaccine was administered to a 10 yr old patient.) and NO ADVERSE EVENT (No adverse event) in a 10-year-old patient of an unknown gender who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. AR6965B) for COVID-19 prophylaxis.     No Medical History information was reported.    On 01-Dec-2022, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 01-Dec-2022, the patient experienced EXPIRED PRODUCT ADMINISTERED (An expired dose of Moderna Covid-19 vaccine was administered to a 10 yr old patient.). On an unknown date, the patient experienced NO ADVERSE EVENT (No adverse event). At the time of the report, EXPIRED PRODUCT ADMINISTERED (An expired dose of Moderna Covid-19 vaccine was administered to a 10 yr old patient.) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessment was provided for EXPIRED PRODUCT ADMINISTERED (An expired dose of Moderna Covid-19 vaccine was administered to a 10 yr old patient.).    No concomitant information was reported. The 2.5 ml of 1 dose vial was initially stored in the refrigerator on 01-Dec-2022 from freezer to room temperature and did not underwent any temperature excursions. No treatment information was provided.
Information has been received from a licensed practical nurse concerning a 25 year old female who on 26-JUL-2007 was vaccinated with a second dose of Gardasil.  Concomitant therapy included hormonal contraceptives (unspecified).  Subsequently the patient experienced a menstrual period that was two weeks long and much heavier than usual.  A urine pregnancy test was performed before the vaccination, and the patient was not pregnant.  Unspecified medical attention was sought.  At the time of the report the patient's outcome was unknown.  Additional information has been requested.
Inquired about administering the second dose to a patient who is 16 years old; 16 years old patient received the first dose of the Moderna vaccine/inquired about administering the second dose to a patient who was 16 years old; This spontaneous case was reported by a nurse and describes the occurrence of PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (16 years old patient received the first dose of the Moderna vaccine/inquired about administering the second dose to a patient who was 16 years old) and OFF LABEL USE (Inquired about administering the second dose to a patient who is 16 years old) in a 16-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 03-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 03-Feb-2021, the patient experienced PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (16 years old patient received the first dose of the Moderna vaccine/inquired about administering the second dose to a patient who was 16 years old). On 16-Mar-2021, the patient experienced OFF LABEL USE (Inquired about administering the second dose to a patient who is 16 years old). On 03-Feb-2021, PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (16 years old patient received the first dose of the Moderna vaccine/inquired about administering the second dose to a patient who was 16 years old) had resolved. At the time of the report, OFF LABEL USE (Inquired about administering the second dose to a patient who is 16 years old) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   The reporter was a registered Nurse who was helping to administer vaccine in the clinic, and inquired about administering the second dose to a patient who was 16 years old and has received already the first dose of the Moderna vaccine 41 days ago, on 03-Feb-2021.  No Concomitant product use was reported. No treatment information was provided.
Post first vax, two hours later, pt experienced flu like symptoms with chills, weakness, dizziness, and tiredness. She also had severe injection site upper arm pain. Psot second dose same day her entire arm was hurting and muscle hurting. She was treated with Advil.
Sudden hearing loss, tinnitus- hearing test, visit to ENT, prednisone given, no resolution
Large red welt (hard/quarter-sized), very hot; now itchy & still a red spot 7 days later (now penny sized).
left arm pain, patient claims unable to use arm - patient says they took tylenol but did not help and is going to emergency room
This spontaneous report as received from a healthcare student refers to a patient of unknown age and gender. On an unknown date the patient was vaccinated with a dose of ZOSTAVAX, subcutaneous in the abdomen (lot # and dosage not reported). No adverse effects reported. Additional information has been requested.
Initial misuse report received on 03 DECEMBER 2013 from nurse. A patients whose gender, age, medical history and concomitant medications were not reported, received a dose of ADACEL (lot number, route and site of vaccination was not reported) on an unspecified date. Patient administered Td vaccine last week but was suppose to have been administered a TDap. Patient did not have any adverse events. List of documents held by sender: none
Initial unsolicited report received from a nurse on 03-Nov-2017. This case involves a 10-year-old male patient who was vaccinated with a 0.5 ml single dose of FLUZONE QUADRIVALENT (batch number: UT5911MA) in right deltoid via intramuscular route on 01-Nov-2017. The patient's has no history of bleeding disorders or other medical problems, only seasonal allergies. The patient's concomitant medications were not reported. On 02-Nov-2017, one day following the vaccination, the patient's injection site started to ooze blood. It was reported that they put on a bandaid and it stopped but, overnight the bleeding started again. It's only a small amount but, they were concerned it's still bleeding days later. Nurse advised to have evaluated for hematoma at the injection site. The patient's laboratory data and corrective treatment were not reported. At the time of report the patient was not recovered from the events. List of documents held by sender: none.
got both shots / one in each arm  / arms were sore for a couple of days but was fine after that!; got two shots one in each arm / got both shots on the same day / that was in 5/18/2021; This case was reported by a consumer via interactive digital media and described the occurrence of pain in arm in a patient who received Herpes zoster (Shingles vaccine) for prophylaxis.   Co-suspect products included Herpes zoster (Shingles vaccine) for prophylaxis.   On 18th May 2021, the patient received the 1st dose of Shingles vaccine and the 2nd dose of Shingles vaccine. On 18th May 2021, not applicable after receiving Shingles vaccine and unknown after receiving Shingles vaccine, the patient experienced overdose. On an unknown date, the patient experienced pain in arm. On an unknown date, the outcome of the pain in arm and overdose were unknown.   It was unknown if the reporter considered the pain in arm to be related to Shingles vaccine and Shingles vaccine.  Additional details were provided as follows: The patient self reported the case. The age at vaccination was not reported. The patient got both shots on the same day one in each arm which led to Over dose. The patient experienced sore arms for a couple of days after receiving vaccine and was fine after that. This case has been linked with case US2021AMR148491, reported by the same reporter.   Follow up information was received from consumer on 7th July 2021: The patient got the vaccine for shingles a long time ago, one shot in each arm. The reporter mentioned that if he/she wanted it otherwise patient would come back for the second and took in each arm.; Sender's Comments:  US-GLAXOSMITHKLINE-US2021AMR148491:Same reporter